Home › Phenylketonuria › NCT06971731
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria
Who can join
Ages 4 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Male or female participants aged 4 years or older. 2. Diagnosed with phenylketonuria. 3. Have phenylalanine levels that meet study requirements. 4. Meet study-specific requirements regarding current treatment for phenylketonuria. 5. Willing and able to follow study dietary requirements. 6. Weigh at least 12.5 kilograms. 7. If able to become pregnant or father a child, willing to follow the study's contraception requirements. 8. Any ongoing mental health condition must be stable before entering the study. 9. Able to provide informed consent (or have consent provided by a parent or legal guardian, when applicable) and comply with study procedures. Exclusion Criteria: Participants will be excluded from the study if any of the following criteria are met: 1. Significant medical condition that, in the investigator's opinion, could make participation unsafe or interfere with study participation. 2. Significant liver disease or impaired kidney function. 3. Certain eye conditions, including significant cataracts. 4. Active infection requiring medical evaluation. 5. History of certain cancers within the past 5 years. 6. Allergy or hypersensitivity to JNT-517 or its ingredients. 7. Prior treatment with JNT-517. 8. Recent participation in another investigational study or receipt of an investigational treatment that does not meet study requirements. 9. Use of medications that are not permitted during the study. 10. Abnormal laboratory or heart test results that would make study participation inappropriate. 11. Conditions that could affect the absorption of oral study medication. 12. History of recent substance or alcohol abuse. 13. Unwillingness to follow study requirements, including restrictions on intentional weight loss.
About the study
This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria.
Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.
What is being tested
- JNT-517 (drug)
- JNT-517 Matching Placebo (drug)
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Participants: 120 · Started: Oct 20, 2025
Contact the study team
- Otsuka Call Center · Phone: 844-687-8522
Official record on ClinicalTrials.gov — NCT06971731
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.